Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pulmonary pharmacokinetics of inhaled budesonide suspension in COPD
ChiCTR2500103135Phase 4Not yet recruiting
- Sponsor
- Clinical Trial Center of Third Xiangya Hospital of Central South University
- Start
- May 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of budesonide in chronic obstructive pulmonary disease (COPD), sponsored by Clinical Trial Center of Third Xiangya Hospital of Central South University. Primary endpoints: Concentration of budesonide in bronchoalveolar lavage fluid and Concentration of budesonide in plasma. Planned start May 2025; status: not yet recruiting.
02
Drugs
budesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2500103135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500103135.